01
Cash & equivalents decreased 23.6%
Cash & equivalents changed -23.6% from the comparable as-filed period.
$20.6M→$15.8MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTTvardi Therapeutics, Inc.'s latest supported as-filed period reports revenue of $2.6M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -23.6% from the comparable as-filed period.
Net income changed -255.0% from the comparable as-filed period.
Operating income changed +25.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TVRD · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-096424SEC ↗8-KAug 14, 2026Period Aug 14, 20260001104659-26-096417SEC ↗8-KJul 30, 2026Period Jul 30, 20260001104659-26-088461SEC ↗8-KJul 17, 2026Period Jul 17, 20260001104659-26-084627SEC ↗8-KJul 7, 2026Period Jul 7, 20260001104659-26-080930SEC ↗4Jun 11, 2026Period Jun 9, 20260001811463-26-000002SEC ↗4Jun 11, 2026Period Jun 9, 20260001609480-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 9, 2026Filed Jun 11, 2026 | Shiff Susan Ph.D.Director | Grant Or AwardDirect | 6,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -31.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed -46.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001588861-26-000002